Novo Nordisk shares gain more than 2% after unveiling major repurchase program and reporting strong sales growth

Traders Union
All News
Stocks
Novo Nordisk rises 2.16% today

Highlights

Novo Nordisk completed a DKK 9.33 billion share repurchase, proposed a higher dividend, and set a new $2.1 billion buyback plan.
Sales grew strongly in 2025 results, led by obesity therapies, US market gains, and an AI partnership with Anthropic for drug discovery.
Shares of Novo Nordisk trade below key moving averages, with oversold momentum signals and an expected five-day range of $41.18 to $43.73.

New buyback and dividend boost as obesity drugs drive sales

Novo Nordisk completed the repurchase of 33,084,179 B shares for DKK 9.33 billion and introduced a new $2.1 billion share buyback alongside a higher proposed dividend. The company also adopted a new corporate brand identity and reported strong sales growth in its 2025 financial results, mainly driven by obesity treatments and US market performance. Novo Nordisk announced a partnership with Anthropic to use AI for drug discovery and is set to present new data on Wegovy at an upcoming medical conference.

Anton Kharitonov, expert at Traders Union, sees Novo Nordisk’s technical setup as persistently weak despite recent news. The stock is trading below major moving averages, showing sellers still dominate. Momentum signals like the MACD, ADX, and Awesome Oscillator all point to further downside pressure. Even with oversold readings on RSI and CCI, the bounce looks fragile in a broader downtrend. "I view the latest buyback and rebound as providing little sustained relief — persistent technical headwinds keep downside risks high."

Viktoras Karapetjanc, expert at Traders Union, highlights Novo Nordisk’s robust fundamentals and strong strategic execution. The successful share buyback, higher dividend, and partnerships in AI-driven drug discovery reflect management’s commitment to growth. Solid sales performance in obesity treatments and renewed investor rewards reinforce a positive long-term story. Karapetjanc states, "The bullish structure remains intact — I see multiple opportunities for further growth as Novo Nordisk aggressively innovates and rewards shareholders."

Sholanke Dele, market strategist, questions the durability of today’s relief bounce. He notes that recent gains are overshadowed by broader market caution and fading momentum. Weak trend strength and high probability of a downward move indicate that sentiment remains fragile. "Short-lived upside is not enough to shift the broader sentiment — I remain cautious until clear strength returns above key support levels."

Oversold signals diverge from gains as sellers retain momentum

Novo Nordisk is trading below its 20-day, 50-day, and 200-day moving averages at $45.49, $47.13, and $46.2, respectively, indicating short-, medium-, and long-term pressure from sellers. The near-term ceiling is at $42.72, with support at $41.47, while bullish MA-50 versus MA-200 alignment signals that the long-term trend remains pointed upward. Momentum signals are predominantly bearish, with the MACD and ADX both indicating a negative outlook and weak trend strength. The RSI at 32.88, CCI at -174.21, and Stochastic RSI at 0 all point to oversold conditions. BBP at -1.64 highlights intraday seller dominance and reinforces the oversold outlook, and the negative Awesome Oscillator confirms downside bias. The stock is up $0.9 or 2.16% after opening with an upside gap of approximately $0.76 (1.82%) and is currently near the intraday high. Intraday volatility stands at 3.01%, with trading favoring strength into session highs even as most momentum readings warn of continued downside pressure. The divergence between oversold oscillators and continued upside highlights the risk of a short-lived bounce within a prevailing downtrend.

Earlier, analysts noted that Novo Nordisk was experiencing sustained technical weakness despite constructive corporate developments. The latest rebound confirms ongoing volatility, with traders advised to monitor the $41.47–$42.72 range for signs of either consolidation or a potential directional breakout.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.